zolmitriptan intranasal (TRZ) / Shin Nippon Biomedical Labs - LARVOL DELTA

Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache (J Headache Pain) - KOL: Hans-Christoph Diener; Andreas Straube; P2, N=97; PREVA (NCT01701245); Sponsor: ElectroCore; "The analysis resulted in mean expected yearly costs of €7096.69 for nVNS + SoC and €7511.35 for SoC alone and mean QALY of 0.607 for nVNS + SoC and 0.522 for SoC alone, suggesting that nVNS generates greater health benefits for lower overall cost. Abortive medication costs were 23 % lower with nVNS + SoC than with SoC alone. In the alternative scenarios (i.e. constant rate of response loss and diminishing rate of response loss), nVNS + SoC was more effective and cost saving than SoC alone."

HEOR • P2 data • Migraine KOL

Formulation and evaluation of chitosan-chondroitin sulphate based nasal inserts for zolmitriptan (Biomed Res Int) - "in vitro and in situ release studies demonstrated that formulations F9 and F11 (drug : polymer; 1 : 10) were releasing 90% and 98% zolmitriptan over a period of 8 h....nasal inserts formulated from chitosan-chondroitin sulphate (CH-CS) interpolymer complex (IPC) can be used for delivery of antimigraine drug to brain."

Preclinical • Migraine